Effect of Sotagliflozin on Cardiovascular and Renal Events in Participants With Type 2 Diabetes and Moderate Renal Impairment Who Are at Cardiovascular Risk
A phase 3 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 10584 participants.
Also called NCT03315143
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose prevention
- Phase
- Phase 3
- Enrolled
- 10,584 participants
- Sponsor
- Registry
-
NCT03315143
-
- Other papers using this trial's data
- Effect of sotagliflozin on major adverse cardiovascular events: a prespecified secondary analysis of the SCORED randomised trial
- Sotagliflozin and Kidney Outcomes, Kidney Function, and Albuminuria in Type 2 Diabetes and CKD: A Secondary Analysis of the SCORED Trial
- Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Argentina, Australia, Belgium, Brazil, Bulgaria, Canada, Chile, China, Czechia, Denmark, Estonia, France, Georgia, Germany, Greece, Guatemala, Hungary, India, Israel, Italy, Latvia, Lithuania, Mexico, Netherlands, New Zealand, North Macedonia, Norway, Peru, Poland, Portugal, Puerto Rico, Romania, Russia, Serbia, Slovakia, South Africa, South Korea, Spain, Sweden, Switzerland, Taiwan, Türkiye, Ukraine, United Kingdom
- Registry status
- Terminated
Technical summary
Registry record NCT03315143. Randomized; quadruple masking; primary purpose prevention. Start 2017-12-19 (actual); primary completion 2020-07-08 (actual). Results posted on 2022-10-28.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Effect of Sotagliflozin on Cardiovascular and Renal Events in Participants With Type 2 Diabetes and Moderate Renal Impairment Who Are at Cardiovascular Risk
- Acronym
- SCORED
- Condition
- Heart Failure
- Condition
- Type 2 Diabetes Mellitus
- Condition
- Chronic Kidney Diseases
- Intervention (Drug)
- Sotagliflozin
- Intervention (Drug)
- Placebo
- Lead sponsor
- Lexicon Pharmaceuticals
- Collaborator
- Sanofi
Record details
- Record id
cardio:ct-nct03315143- Content hash
7761ea7e8a701129f22c282e3b46dbb62ee80f31c7aa9fd05f342d5a00478c88